GPX4 and neoplasm: Using various pharmacological inhibitors for ferroptosis suppressors, the authors were able to show that targeting GPX4, that catalyses the oxidation of GSH to GSSG, through the inhibitor RSL3 led to much greater cell death in LAR tumours compared to other TNBC subtypes.